Dr. Haas on Adjuvant Sorafenib or Sunitinib for RCC

Naomi B. Haas, MD
Published: Monday, Mar 02, 2015



Naomi B. Haas, MD, associate professor, Abramson Cancer Center of the University of Pennsylvania, discusses the phase III ASSURE trial which looks at sorafenib or sunitinib for locally advanced renal cell carcinoma (RCC).

It was hypothesized that sorafenib or sunitinib could extend disease-free survival in the adjuvant setting. To test this, patients were classified based on risk (intermediate-high or very high), clear or non-clear histology, ECOG performance status, and surgery approach and treated for a year with either sunitinib, sorafenib, or placebo.

It was found that neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with RCC.

<<< View more from the 2015 GU Cancer Symposium



Naomi B. Haas, MD, associate professor, Abramson Cancer Center of the University of Pennsylvania, discusses the phase III ASSURE trial which looks at sorafenib or sunitinib for locally advanced renal cell carcinoma (RCC).

It was hypothesized that sorafenib or sunitinib could extend disease-free survival in the adjuvant setting. To test this, patients were classified based on risk (intermediate-high or very high), clear or non-clear histology, ECOG performance status, and surgery approach and treated for a year with either sunitinib, sorafenib, or placebo.

It was found that neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with RCC.

<<< View more from the 2015 GU Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x